In contrast, the application of RNAi technology to interfere with TLR4 or anti-TLR4 and IL-10 neutralizing antibodies significantly inhibited the downregulation of E-cadherin and reduced the upregulation of Vimentin and Snail, suggesting that TAMs promote EMT in pancreatic cancer cells partly through TLR4/IL-10 signaling (75). The gene discussed is IL10; the disease is familial pancreatic carcinoma.